Literature DB >> 1535157

Overlap of the p53-responsive element and cAMP-responsive element in the enhancer of human T-cell leukemia virus type I.

N Aoyama1, T Nagase, T Sawazaki, G Mizuguchi, H Nakagoshi, J I Fujisawa, M Yoshida, S Ishii.   

Abstract

The wild-type p53 protein suppresses transformation, but certain missense mutants of p53 can transform cells. Although the wild-type p53 protein contains a transcriptional activation domain, no p53-responsive element has been identified. Here, we identified the p53-responsive element within the Tax-responsive element [21-base-pair (bp) enhancer] of human T-cell leukemia virus type I. Mutation analysis of the 21-bp enhancer indicated that the 16-bp sequence containing the cAMP-responsive element and its surrounding sequence was responsible for p53-induced transactivation. This 16-bp sequence was demonstrated to bind specifically to wild-type human p53 protein in vitro. Using a series of deletion mutants of p53, we showed that almost the entire region of p53 is needed for the transactivating capacity. Furthermore, the transforming mutants of p53 were unable to act as transcriptional activators. The p53-responsive element identified here should be useful to analyze the mechanism by which p53 regulates expression of a set of genes with a negative effect on cellular growth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535157      PMCID: PMC49300          DOI: 10.1073/pnas.89.12.5403

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

3.  Cell proliferation inhibited by MyoD1 independently of myogenic differentiation.

Authors:  V Sorrentino; R Pepperkok; R L Davis; W Ansorge; L Philipson
Journal:  Nature       Date:  1990-06-28       Impact factor: 49.962

4.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.

Authors:  E M Blackwood; R N Eisenman
Journal:  Science       Date:  1991-03-08       Impact factor: 47.728

5.  Identification of p53 as a sequence-specific DNA-binding protein.

Authors:  S E Kern; K W Kinzler; A Bruskin; D Jarosz; P Friedman; C Prives; B Vogelstein
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

6.  Association of human papillomavirus types 16 and 18 E6 proteins with p53.

Authors:  B A Werness; A J Levine; P M Howley
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

7.  Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

Authors:  D I Linzer; A J Levine
Journal:  Cell       Date:  1979-05       Impact factor: 41.582

8.  Presence of a potent transcription activating sequence in the p53 protein.

Authors:  S Fields; S K Jang
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

9.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

Review 10.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

View more
  9 in total

1.  Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin.

Authors:  T Kiyono; A Hiraiwa; S Ishii; T Takahashi; M Ishibashi
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

2.  p53 domains: suppression, transformation, and transactivation.

Authors:  M Reed; Y Wang; G Mayr; M E Anderson; J F Schwedes; P Tegtmeyer
Journal:  Gene Expr       Date:  1993

3.  Purification by DNA affinity precipitation of the cellular factors HEB1-p67 and HEB1-p94 which bind specifically to the human T-cell leukemia virus type-I 21 bp enhancer.

Authors:  G Lombard-Platet; P Jalinot
Journal:  Nucleic Acids Res       Date:  1993-08-25       Impact factor: 16.971

4.  Sequence-specific transcriptional activation is essential for growth suppression by p53.

Authors:  J A Pietenpol; T Tokino; S Thiagalingam; W S el-Deiry; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

5.  p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53.

Authors:  A Ori; A Zauberman; G Doitsh; N Paran; M Oren; Y Shaul
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

6.  Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene.

Authors:  J Zhao; F I Schmieg; D T Simmons; G R Molloy
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53.

Authors:  S J Ullrich; K Sakaguchi; S P Lees-Miller; M Fiscella; W E Mercer; C W Anderson; E Appella
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication.

Authors:  L Duan; I Ozaki; J W Oakes; J P Taylor; K Khalili; R J Pomerantz
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Wild-type p53 binds to the TATA-binding protein and represses transcription.

Authors:  E Seto; A Usheva; G P Zambetti; J Momand; N Horikoshi; R Weinmann; A J Levine; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.